Michael Matson
Stock Analyst at Needham
(2.21)
# 2,805
Out of 5,157 analysts
25
Total ratings
60%
Success rate
4.9%
Average return
Main Sectors:
Stocks Rated by Michael Matson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TFX Teleflex | Maintains: Buy | $408 → $423 | $111.84 | +278.22% | 4 | Jan 31, 2020 | |
| INGN Inogen | Upgrades: Buy | $90 | $6.22 | +1,346.95% | 2 | Nov 6, 2019 | |
| MMSI Merit Medical Systems | Initiates: Buy | $53 | $69.71 | -23.97% | 1 | Apr 20, 2018 | |
| GMED Globus Medical | Upgrades: Buy | n/a | $86.65 | - | 1 | Apr 4, 2018 | |
| RMD ResMed | Upgrades: Hold | n/a | $247.11 | - | 1 | Jan 23, 2018 | |
| BSX Boston Scientific | Upgrades: Strong Buy | n/a | $69.96 | - | 1 | Dec 8, 2017 | |
| KTWO K2 Capital Acquisition | Downgrades: Buy | n/a | $10.05 | - | 2 | Dec 8, 2017 | |
| LIVN LivaNova | Upgrades: Buy | n/a | $61.93 | - | 2 | Sep 15, 2017 | |
| SYK Stryker | Upgrades: Hold | n/a | $358.65 | - | 4 | Aug 25, 2017 | |
| MBLY Mobileye Global | Downgrades: Hold | n/a | $7.90 | - | 1 | Mar 14, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $75.54 | - | 2 | Feb 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $79.15 | - | 1 | Aug 12, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.25 | - | 1 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.76 | - | 1 | Feb 24, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $618.89 | - | 1 | Jan 29, 2016 |
Teleflex
Jan 31, 2020
Maintains: Buy
Price Target: $408 → $423
Current: $111.84
Upside: +278.22%
Inogen
Nov 6, 2019
Upgrades: Buy
Price Target: $90
Current: $6.22
Upside: +1,346.95%
Merit Medical Systems
Apr 20, 2018
Initiates: Buy
Price Target: $53
Current: $69.71
Upside: -23.97%
Globus Medical
Apr 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $86.65
Upside: -
ResMed
Jan 23, 2018
Upgrades: Hold
Price Target: n/a
Current: $247.11
Upside: -
Boston Scientific
Dec 8, 2017
Upgrades: Strong Buy
Price Target: n/a
Current: $69.96
Upside: -
K2 Capital Acquisition
Dec 8, 2017
Downgrades: Buy
Price Target: n/a
Current: $10.05
Upside: -
LivaNova
Sep 15, 2017
Upgrades: Buy
Price Target: n/a
Current: $61.93
Upside: -
Stryker
Aug 25, 2017
Upgrades: Hold
Price Target: n/a
Current: $358.65
Upside: -
Mobileye Global
Mar 14, 2017
Downgrades: Hold
Price Target: n/a
Current: $7.90
Upside: -
Feb 15, 2017
Upgrades: Buy
Price Target: n/a
Current: $75.54
Upside: -
Aug 12, 2016
Downgrades: Hold
Price Target: n/a
Current: $79.15
Upside: -
Mar 3, 2016
Downgrades: Neutral
Price Target: n/a
Current: $1.25
Upside: -
Feb 24, 2016
Downgrades: Hold
Price Target: n/a
Current: $4.76
Upside: -
Jan 29, 2016
Upgrades: Buy
Price Target: n/a
Current: $618.89
Upside: -